Notice of extraordinary general meeting in Prolight Diagnostics AB (publ)
The shareholders in Prolight Diagnostics AB (publ), reg. no. 556570-9499, (the ”Company”) are hereby convened to the extraordinary general meeting to be held on Monday 27 November 2023 at 11 a.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification etc. Shareholders who wish to participate in the extraordinary general meeting must: […]
Prolight Diagnostics publishes investor letter for October 2023
Prolight Diagnostics publishes an investor letter for October 2023. In the investor letter, an interview is given with Karl Bullen, COO at Prolight Diagnostics. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, a first summary of the Congress Annual Scientific Meeting + Clinical Lab Expo in Anaheim, USA is given. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: ub@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics, together with […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, you can read about the launch of the company's new website and that Prolight Diagnostics is now present at the 2023 AACC Annual Scientific Meeting + Clinical Lab Expo in the USA. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics […]
Annual General Meeting of Prolight Diagnostics AB (publ) on 11 May 2023
The Annual General Meeting (AGM) of Prolight Diagnostics AB (publ) took place on 11 May 2023 in Lund. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdiagnostics.se. The AGM resolved in accordance with all of the motions presented in the notification of the AGM. Resolution regarding the adoption of […]
Prolight Diagnostics submits patent applications for multiplex testing and enhancing dynamic range
Prolight Diagnostics ("Prolight") today announces that the company’s subsidiary Psyros Diagnostics (“Psyros”) has submitted two priority patent applications covering various aspects of multiplexing capabilities to the Intellectual Property Office in Great Britain. The first application covers various aspects of multiplexing (i.e., detecting several different biomarkers at the same time on a single sample). By using […]
NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), corp. Reg. no. 556570-9499, (the ”Company”) are hereby notified of the Annual General Meeting to be held on Thursday 11 May 2023 at 2 p.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification of attendanceShareholders who wish to participate in the Annual General Meeting must:– […]
Prolight Diagnostics selects ITL (a G&H Company) to develop commercial instrument
Prolight Diagnostics (“Prolight”) today announces that it has selected Integrated Technologies Limited (“ITL”) to develop the commercial instrument for its point-of-care digital immunoassay system. This next stage of product development builds on the prototypes developed in-house at Prolight’s subsidiary Psyros Diagnostics (“Psyros”) and will ensure that the commercial instrument is state of the art and […]
Prolight Diagnostics Delivers on SBRI Healthcare Grant
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has successfully completed the SBRI Healthcare phase 2 award, accelerating development of its unique digital immunoassay. Psyros received the SBRI Healthcare phase 2 grant of approximately 1 million GBP last year, requiring the completion of certain milestones. Psyros has now met or exceeded all […]
Prolight Diagnostics shows proof-of-performance for high-sensitive immuno assay
Prolight Diagnostics (“Prolight”) today announced that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance that its high-sensitivity immunoassay is capable of reproducibly detecting low levels of specific proteins in a digital manner. “This is a very important step on our journey to develop a high-sensitivity assay for digitally detecting troponin. Such an […]
